Literature DB >> 28070872

Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.

Kornkiat Snidvongs1, Kachorn Seresirikachorn2, Likhit Khattiyawittayakun2, Wirach Chitsuthipakorn3.   

Abstract

INTRODUCTION: As a substrate of P-glycoprotein, levocetirizine should not cause sedative effects. However, while cetirizine, a mixture of levocetirizine and dextrocetirizine, can slightly penetrate the blood brain barrier, the sedative effects of levocetirizine are still under study.
OBJECTIVES: The aim of this study was to investigate the sedative effects of levocetirizine.
METHODS: An electronic literature search was performed using Medline and EMBASE from January 01, 2001 through August 6, 2015. Randomized controlled trials (RCTs) comparing levocetirizine with other antihistamines or placebo for patients with allergy and healthy subjects were selected. Primary outcome was risk ratio between levocetirizine and comparators. Secondary outcome was change in psychomotor speed. Data were pooled for meta-analysis using a fixed-effect model.
RESULTS: Forty-eight studies of 18,014 patients met the inclusion criteria. When compared to placebo, levocetirizine produced modest sedative effects (RR: 1.67; 95% CI 1.17, 2.38). However, when compared to other second-generation antihistamines, sedative effects of levocetirizine did not differ (RR: 1.23; 95% CI 0.96, 1.58). In subgroup analysis, there was no difference between the sedative effects of levocetirizine and fexofenadine (RR: 1.7; 95% CI 0.59, 4.88), desloratadine (RR: 1.58; 95% CI 0.9, 2.77), loratadine (RR: 1.56; 95% CI 0.28, 8.56), bilastine (RR: 1.17; 95% CI 0.48, 2.84), olopatadine (RR: 1.09; 95% CI 0.81, 1.47), azelastine (RR: 0.19; 95% CI 0.01, 3.68) and rupatadine (RR: 1.47; 95% CI 0.14, 15.72). When compared to first-generation antihistamines, levocetirizine had less sedative effects and less change of reaction time (mean difference: -250.76 s; 95% CI -338.53, -162.98).
CONCLUSION: Levocetirizine has modest sedative effects with a risk ratio of 1.67 when compared with placebo. The sedative effects observed for levocetirizine are not different from other second-generation antihistamines.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28070872     DOI: 10.1007/s40265-016-0682-0

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  50 in total

1.  Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration.

Authors:  Friedrich Horak; Petra U Zieglmayer; R Zieglmayer; A Kavina; P Lemell
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study.

Authors:  Nathan Segall; Sandra Gawchik; George Georges; Jean-Marc C Haeusler
Journal:  Ann Allergy Asthma Immunol       Date:  2010-03       Impact factor: 6.347

3.  The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.

Authors:  I Hindmarch; S Johnson; R Meadows; T Kirkpatrick; Z Shamsi
Journal:  Curr Med Res Opin       Date:  2001       Impact factor: 2.580

4.  The comparison of cetirizine, levocetirizine and placebo for the treatment of childhood perennial allergic rhinitis.

Authors:  Chih-Fang Lee; Hai-Lun Sun; Ko-Hsiu Lu; Min-Sho Ku; Ko-Huang Lue
Journal:  Pediatr Allergy Immunol       Date:  2008-10-06       Impact factor: 6.377

5.  Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study.

Authors:  G Ciprandi; I G Cirillo; A Vizzaccaro; M A Tosca
Journal:  Eur Ann Allergy Clin Immunol       Date:  2005-01

6.  Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis.

Authors:  M L Barnes; J H Ward; T C Fardon; B J Lipworth
Journal:  Clin Exp Allergy       Date:  2006-05       Impact factor: 5.018

7.  Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.

Authors:  P C Potter; A Kapp; M Maurer; G Guillet; A M Jian; P Hauptmann; A Y Finlay
Journal:  Allergy       Date:  2008-11-11       Impact factor: 13.146

8.  Loratadine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety.

Authors:  P Anuradha; Rituparna Maiti; J Jyothirmai; Omer Mujeebuddin; M Anuradha
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

9.  Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.

Authors:  J M Gandon; H Allain
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 10.  A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.

Authors:  Claus Bachert
Journal:  Clin Ther       Date:  2009-05       Impact factor: 3.393

View more
  6 in total

1.  A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.

Authors:  Marco Folci; Giacomo Ramponi; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  The Effect Of Food On The Pharmacokinetic Properties And Bioequivalence Of Two Formulations Of Levocetirizine Dihydrochloride In Healthy Chinese Volunteers.

Authors:  Yu Cheng; Bi-Juan Lin; Jin-Hua Guo; Bing-Lin Huang; Lin-Ping Fang; Wan-Cai Que; Mao-Bai Liu; Xin-Feng Chen; Hong-Qiang Qiu
Journal:  Drug Des Devel Ther       Date:  2019-10-18       Impact factor: 4.162

Review 3.  Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis.

Authors:  Aranjit Singh Randhawa; Norhayati Mohd Noor; Mohd Khairi Md Daud; Baharudin Abdullah
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

4.  Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology.

Authors:  Baharudin Abdullah; Amir Hamzah Abdul Latiff; Anura Michelle Manuel; Faizah Mohamed Jamli; Harvinder Singh Dalip Singh; Intan Hakimah Ismail; Jeevanan Jahendran; Jeyasakthy Saniasiaya; Kent Chee Keen Woo; Phaik Choo Khoo; Kuljit Singh; Nurashikin Mohammad; Sakinah Mohamad; Salina Husain; Ralph Mösges
Journal:  J Asthma Allergy       Date:  2022-08-02

5.  Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.

Authors:  Cheng-Zhi Huang; Zhi-Hui Jiang; Jian Wang; Yue Luo; Hua Peng
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-29       Impact factor: 2.483

6.  IV Brazilian Consensus on Rhinitis - an update on allergic rhinitis.

Authors:  Eulalia Sakano; Emanuel S C Sarinho; Alvaro A Cruz; Antonio C Pastorino; Edwin Tamashiro; Fábio Kuschnir; Fábio F M Castro; Fabrizio R Romano; Gustavo F Wandalsen; Herberto J Chong-Neto; João F de Mello; Luciana R Silva; Maria Cândida Rizzo; Mônica A M Miyake; Nelson A Rosário Filho; Norma de Paula M Rubini; Olavo Mion; Paulo A Camargos; Renato Roithmann; Ricardo N Godinho; Shirley Shizue N Pignatari; Tania Sih; Wilma T Anselmo-Lima; Dirceu Solé
Journal:  Braz J Otorhinolaryngol       Date:  2017-11-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.